Pyxis Oncology/PYXS

$3.78

-1.05%
-
1D1W1MYTD1YMAX

About Pyxis Oncology

Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes PYX-201, PYX-106 and PYX-107. PYX-201, an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-107 is a CD40 agonist antibody designed to maximize its agonistic properties. Its therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its ADC and immuno-oncology (IO) programs target a range of solid tumors resistant to current standards of care.

Ticker

PYXS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Lara Sullivan

Employees

51

Headquarters

Boston, United States

Pyxis Oncology Metrics

BasicAdvanced
$230M
Market cap
-
P/E ratio
-$1.39
EPS
-
Beta
-
Dividend rate
$230M
$6.85
$1.35
702K
12.19
-28.68%
-34.37%
-30.64%
14.224
1.245
1.432
56.95%

What the Analysts think about Pyxis Oncology

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
133.6% upside
High $12.00
Low $7.00
$3.78
Current price
$8.83
Average price target

Pyxis Oncology Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-19.87% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$16M
∞%
Net income
-$3.2M
-79.35%
Profit margin
-19.87%
-∞%

Pyxis Oncology Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 75.21%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.41
-$0.56
-$0.33
-$0.06
-
Expected
-$0.65
-$0.51
-$0.48
-$0.24
-$0.32
Surprise
-36.68%
10.53%
-30.53%
-75.21%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Pyxis Oncology stock?

Pyxis Oncology (PYXS) has a market cap of $225M as of May 25, 2024.

What is the P/E ratio for Pyxis Oncology stock?

The price to earnings (P/E) ratio for Pyxis Oncology (PYXS) stock is 0 as of May 25, 2024.

Does Pyxis Oncology stock pay dividends?

No, Pyxis Oncology (PYXS) stock does not pay dividends to its shareholders as of May 25, 2024.

When is the next Pyxis Oncology dividend payment date?

Pyxis Oncology (PYXS) stock does not pay dividends to its shareholders.

What is the beta indicator for Pyxis Oncology?

Pyxis Oncology (PYXS) does not currently have a Beta indicator.

What is the Pyxis Oncology stock price target?

The target price for Pyxis Oncology (PYXS) stock is $8.83, which is 131.76% above the current price of $3.81. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Pyxis Oncology stock

Buy or sell Pyxis Oncology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing